We are shaping the future of stem cell therapies

Our platform removes unwanted cells, one of the major bottlenecks and risks in cell therapy manufacture.

CTA Button
Shape pattern gifShape pattern gif

Understanding Our Process

Stage 1 of process image

We harness deep analytics to precisely pinpoint impurities in stem cell products.

Our flexible workflow seamlessly integrates with diverse starting materials in any laboratory setting—yours or ours.

Stage 2 of process image

We then create and validate a custom component to include during the differentiation.

We use cutting-edge design and manufacturing methods to produce a working product in just a few months.

Stage 3 of process image

This new component removes impurities, resulting in a 'Plurified' product.

Leaving no trace behind, our scalable process guarantees a safer, higher-quality product.

We are a small team with a big vision for the future of cell therapy.

We are always looking for partners and team members who share that vision. Reach out if you would like to connect.

Image of the Plurify team

Meet Our Team

Image of Djordje Djordjevic

Djordje Djordjevic, PhD
Co-founder & CEO

A seasoned bioinformatics specialist, Djordje combines his patient-centric industry knowledge with technical expertise and data-driven thinking to solve major challenges in stem cell therapies.

Image of Mantas Matjusaitis

Mantas Matjusaitis, PhD
Co-founder & CTO

Mantas is an expert is synthetic biology and molecular cloning for advanced cell and gene therapies, having driven innovation in multiple biotech organisations, from startups to pharma.

Image of Daniel Ortmann

Daniel Ortmann, PhD
Scientific Co-founder

Over a decade driving projects at leading PSC labs and biotechs has cemented Daniel as a world class stem cell biologist with deep knowledge of the challenges of cellular purity across many protocols.

Board and Advisors

Image of Kerstin Papenfuss

Kerstin Papenfuss, PhD
Director Pharma, Deep Science Ventures

Board Member

Our board member Kerstin has extensive experience building, launching and supporting over a dozen biotechs in advanced cell and gene therapies.

Jeanette Evans
CBO, Cell and Gene Therapy Catapult

Board Member

Jeanette brings to our board her deep understanding of business development and deal making, developed over her two decades in cutting-edge biotech and big pharma.

Image of Ricardo Baptista

Ricardo Baptista, Eng PhD
CTO, SmartCella

Advisor

A true pioneer and expert in the therapeutic cell manufacturing field, Ricardo combines extensive CMC and MSAT knowledge with quality and regulatory strategies.

Image of Keith Thompson

Keith Thompson, CBE
Multiple chairs

Advisor

As the former CEO of the Cell and Gene Therapy Catapult, Keith has been a driving force behind the development, commercialization and adoption of the cell and gene therapy industry across the UK.

Image of Jonathan Appleby

Jonathan Appleby, PhD
Former CSO, GSK and Cell and Gene Therapy Catapult

Advisor

Jonathan has decades of industrial scientific leadership experience, taking cutting-edge cell and gene therapies all the way to market.